Webinar on Infex’s Phase II lead respiratory drug, RESP-X

On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with our lead Phase II asset, RESP-X.

Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?

Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new…

Antimicrobial discovery and drug development – RSC Podcast

How do we develop drugs like antibiotics? How long does it take for such a drug to go from its inception in a research lab to use in a…

World Antibiotic Awareness Week Video

This week is World Antibiotic Awareness Week.

Industry group calls for action over £500m funding gap on AMR

A life science industry report representing 36 key businesses and organisations concerned about the growing impact of anti-microbial…

Podcast: Tackling The AMR Crisis

In this podcast Mike Ward of Informa talks to Dr Peter Jackson, executive director of the AMR Centre.

Publications authored by Infex Therapeutics scientists:



  • N Ooi, V E Lee, N Chalam-Judge, R Newman, A J Wilkinson, I R Cooper, D Orr, S Lee and V J Savage. Restoring carbapenem efficacy: a novel carbapenem companion targeting metallo-β-lactamases in carbapenem-resistant Enterobacterales. Journal of Antimicrobial Chemotherapy 2021; 76(2): 460–466. https://doi.org/10.1093/jac/dkaa455




  • A J Wilkinson, N Ooi, J Finlayson, V E Lee, D Lyth, K S Maskew, R Newman, D Orr, K Ansell, K Birchall, P Canning, P Coombs, L Fusani, E McIver, J Pisco, P M Ireland, C Jenkins, I H Norville, S J Southern, R Cowan, G Hall, C Kettleborough, V J Savage, I R Cooper. Evaluating the druggability of TrmD, a potential antibacterial target, through design and microbiological profiling of a series of potent TrmD inhibitors. Bioorganic & Medicinal Chemistry Letters 2023; 90: 129331-129338. https://doi.org/10.1016/j.bmcl.2023.129331


  • N Ooi, I R Cooper, B Norman, J A Gallagher, N Sireau, G Bou-Gharios, L R Ranganath, V J Savage. Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial. Cells 2023, 12(13), 1683. https://www.mdpi.com/2073-4409/12/13/1683


  • Adam O Whelan, Ian Cooper, Nicola Ooi, David Orr, Kevin Blades, James Kirkham, Amanda Lyons, Kay B Barnes, Mark I Richards, Anne-Marie Salisbury, Mark Craighead, Sarah V Harding. In Vitro Activity of Novel Topoisomerase Inhibitors against Francisella tularensis and Burkholderia pseudomallei. Antibiotics (Basel) . 2023 May 30;12(6):983. doi: 10.3390/antibiotics12060983. https://pubmed.ncbi.nlm.nih.gov/37370302/